Inbrx 105 Graphic

The Candidate

Our tumor-targeted 4-1BB agonist.

INBRX-105 is a PD-L1 dependent 4-1BB agonist designed to:

  • Achieve 4-1BB agonism only at sites of PD-L1 expression.
  • Provide local co-stimulation to tumor-infiltrating lymphocytes (TILs) and boost anti-tumor T-cell activity.
  • Avoid the hepatotoxicity liability of systemic 4-1BB agonism.

Building on the Current Foundations

Inhibrx Lab 04

The approval of checkpoint inhibitors that block the interaction between PD-L1 and programmed cell death protein 1, or PD-1, has shifted the treatment paradigm of numerous cancers, due to improved response rates and overall survival benefit.

These therapeutics, however, achieve a lasting benefit only for a minority of patients and numerous combination approaches have been tested clinically with the goal of further activating tumor reactive T-cells. One such approach is agonist antibodies targeting 4-1BB, a member of the TNFRSF that has been shown to provide co-stimulatory function to T-cells. While 4-1BB agonism has shown some clinical promise, the efficacy seen with this approach has been limited due to dose limiting toxicities that result from systemic activation of 4-1BB.

We believe INBRX-105 has the potential to selectively activate 4-1BB + T-cells in the tumor microenvironment only, thus overcoming the toxicity issues that have limited prior 4-1BB agonists.

Inhibrx Clinical Trials

INBRX-105 Clinical Trial

The Phase 1 trial for INBRX-105 completed Part 1, single agent dose escalation, and is currently enrolling Parts 2 and 4, single agent dose expansion and dose expansion in combination with Keytruda, in the following tumor types:

  • Metastatic Solid Tumors
  • Non-Small Cell Lung Cancer (NSCLC)
  • Melanoma
  • Head and Neck Squamous Cell Carcinoma
  • Gastric Adenocarcinoma
  • Renal Cell Carcinoma (RCC)
  • Urothelial Carcinoma
  • Esophageal Adenocarcinoma